Richard Davies

Directeur/Membre du Conseil chez ALVOTECH Fortune : 4 M $ au 31/05/2026

Profil

Richard John Davies currently works at Auregen Biotherapeutics SA, as Chief Executive Officer from 2018, Auregen Biotherapeutics, Inc., as Chief Executive Officer, Immodulon Therapeutics Ltd., as Chairman from 2023, Bone Support Incentive AB, as Chairman, Alvotech hf, as Deputy Chairman, and Alvotech, as Deputy Chairman from 2019.
Mr. Davies also formerly worked at BONESUPPORT HOLDING AB, as Chief Executive Officer from 2016 to 2018, BONE SUPPORT AB, as Chief Executive Officer from 2016 to 2018, Amgen, Inc., as Vice President & General Manager-Asia Pacific from 2003 to 2012, Eli Lilly & Co., as General Manager-Poland & Baltics, Hospira, Inc., as Chief Commercial Officer & Senior Vice President from 2012 to 2015, Amgen KK, as Vice President & General Manager in 2012, and Amgen Australia Pty Ltd., as General Manager in 2008.
Mr. Davies received his Masters Business Admin degree from the University of Warwick and undergraduate degree from the University of Portsmouth.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
ALVOTECH 0,38%	06/03/2026	1 193 992 ( 0,38% )	4 M $	31/05/2026

Postes actifs de Richard Davies

Sociétés	Poste	Début
ALVOTECH	Directeur/Membre du Conseil	01/01/2019
Bone Support Incentive AB	Président	-
Alvotech hf	Directeur/Membre du Conseil	01/01/2016
Auregen Biotherapeutics SA	Directeur Général	20/11/2018
Auregen Biotherapeutics, Inc.	Directeur Général	-
Immodulon Therapeutics Ltd.	Président	10/05/2023

Anciens postes connus de Richard Davies

Sociétés	Poste	Fin
BONESUPPORT HOLDING AB	Directeur Général	01/03/2018
BONE SUPPORT AB	Directeur Général	01/01/2018
HOSPIRA, INC.	Corporate Officer/Principal	01/01/2015
░░░░░ ░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░░░ ░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░